Logo image of VBIV

VBI VACCINES INC (VBIV) Stock Fundamental Analysis

NASDAQ:VBIV - Nasdaq - CA91822J2020 - Common Stock - Currency: USD

0.0653  -0.07 (-50.87%)

After market: 0.045 -0.02 (-31.09%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VBIV. VBIV was compared to 551 industry peers in the Biotechnology industry. VBIV has a bad profitability rating. Also its financial health evaluation is rather negative. VBIV shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VBIV has reported negative net income.
In the past year VBIV has reported a negative cash flow from operations.
VBIV had negative earnings in each of the past 5 years.
In the past 5 years VBIV always reported negative operating cash flow.
VBIV Yearly Net Income VS EBIT VS OCF VS FCFVBIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -111.34%, VBIV is doing worse than 80.07% of the companies in the same industry.
Industry RankSector Rank
ROA -111.34%
ROE N/A
ROIC N/A
ROA(3y)-71.38%
ROA(5y)-56.21%
ROE(3y)-490.56%
ROE(5y)-312.13%
ROIC(3y)N/A
ROIC(5y)N/A
VBIV Yearly ROA, ROE, ROICVBIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VBIV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VBIV Yearly Profit, Operating, Gross MarginsVBIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

VBIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VBIV has been increased compared to 1 year ago.
The number of shares outstanding for VBIV has been increased compared to 5 years ago.
VBIV has a worse debt/assets ratio than last year.
VBIV Yearly Shares OutstandingVBIV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
VBIV Yearly Total Debt VS Total AssetsVBIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -13.90, we must say that VBIV is in the distress zone and has some risk of bankruptcy.
VBIV's Altman-Z score of -13.90 is on the low side compared to the rest of the industry. VBIV is outperformed by 83.22% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.9
ROIC/WACCN/A
WACC9.93%
VBIV Yearly LT Debt VS Equity VS FCFVBIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.34 indicates that VBIV may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.34, VBIV is doing worse than 95.80% of the companies in the same industry.
VBIV has a Quick Ratio of 0.34. This is a bad value and indicates that VBIV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.21, VBIV is not doing good in the industry: 97.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.34
Quick Ratio 0.21
VBIV Yearly Current Assets VS Current LiabilitesVBIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for VBIV have decreased strongly by -90.48% in the last year.
VBIV shows a strong growth in Revenue. In the last year, the Revenue has grown by 548.76%.
The Revenue has been growing by 20.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-90.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.33%
Revenue 1Y (TTM)548.76%
Revenue growth 3Y101.58%
Revenue growth 5Y20.91%
Sales Q2Q%150.31%

3.2 Future

Based on estimates for the next years, VBIV will show a very strong growth in Earnings Per Share. The EPS will grow by 25.46% on average per year.
VBIV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.62% yearly.
EPS Next Y86.5%
EPS Next 2Y40.33%
EPS Next 3Y25.46%
EPS Next 5YN/A
Revenue Next Year-2.62%
Revenue Next 2Y60.85%
Revenue Next 3Y64.62%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VBIV Yearly Revenue VS EstimatesVBIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
VBIV Yearly EPS VS EstimatesVBIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VBIV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VBIV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VBIV Price Earnings VS Forward Price EarningsVBIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VBIV Per share dataVBIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as VBIV's earnings are expected to grow with 25.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.33%
EPS Next 3Y25.46%

More info and screens

0

5. Dividend

5.1 Amount

VBIV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VBI VACCINES INC

NASDAQ:VBIV (8/7/2024, 8:00:02 PM)

After market: 0.045 -0.02 (-31.09%)

0.0653

-0.07 (-50.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2024-08-07/bmo
Earnings (Next)11-12 2024-11-12/bmo
Inst Owners0.03%
Inst Owner Change-99.13%
Ins Owners66.54%
Ins Owner Change0%
Market Cap1.87M
Analysts82.86
Price Target5.1 (7710.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.25%
Min EPS beat(2)-35.04%
Max EPS beat(2)95.54%
EPS beat(4)1
Avg EPS beat(4)-169%
Min EPS beat(4)-607.28%
Max EPS beat(4)95.54%
EPS beat(8)1
Avg EPS beat(8)-125.37%
EPS beat(12)4
Avg EPS beat(12)-83.31%
EPS beat(16)5
Avg EPS beat(16)-65.27%
Revenue beat(2)0
Avg Revenue beat(2)-71.33%
Min Revenue beat(2)-84.4%
Max Revenue beat(2)-58.27%
Revenue beat(4)0
Avg Revenue beat(4)-54.42%
Min Revenue beat(4)-84.4%
Max Revenue beat(4)-24.02%
Revenue beat(8)0
Avg Revenue beat(8)-59.02%
Revenue beat(12)1
Avg Revenue beat(12)-48.87%
Revenue beat(16)1
Avg Revenue beat(16)-48.12%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)31.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-35.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.8
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0.33
BVpS-0.19
TBVpS-1.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -111.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.38%
ROA(5y)-56.21%
ROE(3y)-490.56%
ROE(5y)-312.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.73%
Cap/Sales 5.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.34
Quick Ratio 0.21
Altman-Z -13.9
F-Score4
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)120.98%
Cap/Depr(5y)145.88%
Cap/Sales(3y)243.1%
Cap/Sales(5y)197.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.33%
EPS Next Y86.5%
EPS Next 2Y40.33%
EPS Next 3Y25.46%
EPS Next 5YN/A
Revenue 1Y (TTM)548.76%
Revenue growth 3Y101.58%
Revenue growth 5Y20.91%
Sales Q2Q%150.31%
Revenue Next Year-2.62%
Revenue Next 2Y60.85%
Revenue Next 3Y64.62%
Revenue Next 5YN/A
EBIT growth 1Y44.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.15%
OCF growth 3YN/A
OCF growth 5YN/A